J-Star — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

J-STAR Research is an established, privately-held contract service provider focused on process chemistry, crystallization, analytical development, and cGMP manufacturing for small molecule therapeutics. The company differentiates itself through a strong technology platform featuring high-throughput experimentation (HTE), continuous flow, computational chemistry, and capabilities in handling potent compounds and controlled substances. As part of the larger Porton Pharma Solutions group, J-STAR leverages its New Jersey-based facilities and scientific expertise to serve as an outsourcing partner for pharmaceutical and biotech clients globally, aiming to reduce development timelines and de-risk programs.

Small MoleculesDrug Delivery

Technology Platform

Integrated suite of process R&D technologies including High-Throughput Experimentation (HTE), Computational Chemistry & Data Science, Continuous Flow, High-Pressure Chemistry, and specialized capabilities for Crystallization R&D, Potent Compounds (HPAPI), and Controlled Substances.

Opportunities

The growing trend of pharmaceutical outsourcing and the increasing complexity of small molecule drug development create strong demand for J-STAR's integrated, technology-driven CMC services.

Its specialization in high-potent compounds and controlled substances addresses a niche with high technical barriers and less competition.

Risk Factors

Key risks include high competition in the CDMO sector, dependence on the biotech funding environment for new projects, and significant operational/regulatory risks associated with cGMP manufacturing and handling of controlled substances.

As a service provider, client concentration is also a potential vulnerability.

Competitive Landscape

J-STAR competes in the fragmented but competitive CDMO market, facing rivals ranging from large, full-service global CDMOs (e.g., Lonza, Catalent) to smaller, niche chemistry specialists. Its differentiation lies in its deep focus on integrated small molecule process R&D, advanced technology platform, and potent/controlled substance capabilities, rather than large-scale commercial manufacturing.

More companies in Small Molecule Drugs →More companies in United States →